Zhengye Biotechnology (ZYBT) Competitors

$0.86 -0.07 (-7.37%)

As of 03:03 PM Eastern

ZYBT vs. ENLV, HRTX, PRQR, IFRX, and DERM

Should you buy Zhengye Biotechnology stock or one of its competitors? MarketBeat compares Zhengye Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zhengye Biotechnology include Enlivex Therapeutics (ENLV), Heron Therapeutics (HRTX), ProQR Therapeutics (PRQR), InflaRx (IFRX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enlivex Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, suggesting that its stock price is 347% less volatile than the broader market.

Enlivex Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 2,237.11%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enlivex Therapeutics' return on equity of 248.08% beat Zhengye Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Zhengye Biotechnology	N/A	N/A	N/A

In the previous week, Enlivex Therapeutics had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 0 mentions for Zhengye Biotechnology. Enlivex Therapeutics' average media sentiment score of 0.25 beat Zhengye Biotechnology's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Zhengye Biotechnology	Neutral

Enlivex Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

Summary

Enlivex Therapeutics beats Zhengye Biotechnology on 11 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Zhengye Biotechnology has lower revenue, but higher earnings than Heron Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	1.09	-$20.19M	-$0.18	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

80.0% of Heron Therapeutics shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Heron Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 420.83%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Heron Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Heron Therapeutics had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Heron Therapeutics and 0 mentions for Zhengye Biotechnology. Heron Therapeutics' average media sentiment score of 0.01 beat Zhengye Biotechnology's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Neutral
Zhengye Biotechnology	Neutral

Heron Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market.

Zhengye Biotechnology has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Zhengye Biotechnology's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Heron Therapeutics beats Zhengye Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to ProQR Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Zhengye Biotechnology has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Zhengye Biotechnology's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Zhengye Biotechnology has a beta of -2.47, indicating that its stock price is 347% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

32.7% of ProQR Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ProQR Therapeutics had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for ProQR Therapeutics and 0 mentions for Zhengye Biotechnology. ProQR Therapeutics' average media sentiment score of 0.30 beat Zhengye Biotechnology's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
ProQR Therapeutics	Neutral

Zhengye Biotechnology has higher revenue and earnings than ProQR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A
ProQR Therapeutics	$17.99M	8.43	-$47.73M	-$0.50	N/A

ProQR Therapeutics has a consensus target price of $7.25, indicating a potential upside of 403.47%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ProQR Therapeutics beats Zhengye Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

In the previous week, InflaRx had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for InflaRx and 0 mentions for Zhengye Biotechnology. InflaRx's average media sentiment score of 0.53 beat Zhengye Biotechnology's score of 0.00 indicating that InflaRx is being referred to more favorably in the media.

Company	Overall Sentiment
InflaRx	Positive
Zhengye Biotechnology	Neutral

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

InflaRx has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market.

InflaRx presently has a consensus price target of $7.00, suggesting a potential upside of 199.79%. Given InflaRx's stronger consensus rating and higher possible upside, equities analysts clearly believe InflaRx is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Zhengye Biotechnology	N/A	N/A	N/A

Zhengye Biotechnology has higher revenue and earnings than InflaRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	5,626.57	-$51.63M	-$0.71	N/A
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A

Summary

InflaRx beats Zhengye Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Journey Medical?

Zhengye Biotechnology (NASDAQ:ZYBT) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Zhengye Biotechnology has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Journey Medical had 19 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 19 mentions for Journey Medical and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Journey Medical's score of -0.51 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Journey Medical	Negative

Journey Medical has a consensus price target of $13.00, indicating a potential upside of 114.38%. Given Journey Medical's stronger consensus rating and higher possible upside, analysts clearly believe Journey Medical is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Zhengye Biotechnology has higher revenue and earnings than Journey Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.35	-$9.98M	N/A	N/A
Journey Medical	$61.86M	2.68	-$11.43M	-$0.37	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Zhengye Biotechnology's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Journey Medical	-14.82%	-35.57%	-10.88%

7.3% of Journey Medical shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Journey Medical beats Zhengye Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.52M	$3.26B	$6.27B	$12.13B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	N/A	18.70	20.61	25.11
Price / Sales	0.35	281.88	578.26	91.48
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.92	6.59	9.72	6.63
Net Income	-$9.98M	$24.30M	$3.55B	$335.73M
7 Day Performance	-15.35%	-3.36%	-1.89%	-1.80%
1 Month Performance	-13.68%	-7.67%	-3.77%	-1.69%
1 Year Performance	-90.53%	52.30%	29.58%	27.59%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	N/A	$0.86 -7.4%	N/A	-88.2%	$40.52M	$116.36M	N/A	278	Short Interest Decrease
ENLV Enlivex Therapeutics	2.3805 of 5 stars	$0.74 +0.6%	$16.50 +2,138.8%	-30.3%	$174.95M	N/A	N/A	70	News Coverage
HRTX Heron Therapeutics	2.2281 of 5 stars	$0.92 +0.3%	$4.50 +390.7%	-56.4%	$173.57M	$154.90M	N/A	300	Analyst Downgrade
PRQR ProQR Therapeutics	3.4112 of 5 stars	$1.65 -3.2%	$7.25 +340.7%	-6.8%	$173.32M	$15.91M	N/A	180	Earnings Report Analyst Downgrade
IFRX InflaRx	3.5445 of 5 stars	$2.40 -5.0%	$7.00 +192.3%	+50.6%	$173.14M	$29.33K	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ENLV, HRTX, PRQR, IFRX, and DERM

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Summary

How does Zhengye Biotechnology compare to Heron Therapeutics?

Summary

How does Zhengye Biotechnology compare to ProQR Therapeutics?

Summary

How does Zhengye Biotechnology compare to InflaRx?

Summary

How does Zhengye Biotechnology compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ENLV, HRTX, PRQR, IFRX, and DERM

How does Zhengye Biotechnology compare to Enlivex Therapeutics?

Do insiders and institutionals hold more shares of ENLV or ZYBT?

Which has more volatility and risk, ENLV or ZYBT?

Do analysts prefer ENLV or ZYBT?

Is ENLV or ZYBT more profitable?

Does the media prefer ENLV or ZYBT?

Which has stronger valuation & earnings, ENLV or ZYBT?

Summary

How does Zhengye Biotechnology compare to Heron Therapeutics?

Which has stronger earnings & valuation, HRTX or ZYBT?

Do insiders and institutionals believe in HRTX or ZYBT?

Do analysts prefer HRTX or ZYBT?

Does the media refer more to HRTX or ZYBT?

Which has more risk & volatility, HRTX or ZYBT?

Is HRTX or ZYBT more profitable?

Summary

How does Zhengye Biotechnology compare to ProQR Therapeutics?

Is ZYBT or PRQR more profitable?

Which has more risk & volatility, ZYBT or PRQR?

Do institutionals and insiders believe in ZYBT or PRQR?

Does the media prefer ZYBT or PRQR?

Which has preferable valuation & earnings, ZYBT or PRQR?

Do analysts recommend ZYBT or PRQR?

Summary

How does Zhengye Biotechnology compare to InflaRx?

Does the media favor IFRX or ZYBT?

Do insiders & institutionals hold more shares of IFRX or ZYBT?

Which has more risk & volatility, IFRX or ZYBT?

Do analysts rate IFRX or ZYBT?

Is IFRX or ZYBT more profitable?

Which has higher earnings & valuation, IFRX or ZYBT?

Summary

How does Zhengye Biotechnology compare to Journey Medical?

Which has more risk and volatility, ZYBT or DERM?

Does the media refer more to ZYBT or DERM?

Do analysts recommend ZYBT or DERM?

Which has preferable valuation and earnings, ZYBT or DERM?

Is ZYBT or DERM more profitable?

Do institutionals & insiders believe in ZYBT or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools